Cargando…

Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies

Mostrar otras versiones (2)

Many anti-SARS-CoV-2 neutralizing antibodies target the ACE2-binding site on viral spike receptor-binding domains (RBDs). The most potent antibodies recognize exposed variable epitopes, often rendering them ineffective against other sarbecoviruses and SARS-CoV-2 variants. Class 4 anti-RBD antibodies...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jette, Claudia A., Cohen, Alexander A., Gnanapragasam, Priyanthi N.P., Muecksch, Frauke, Lee, Yu E., Huey-Tubman, Kathryn E., Schmidt, Fabian, Hatziioannou, Theodora, Bieniasz, Paul D., Nussenzweig, Michel C., West, Anthony P., Keeffe, Jennifer R., Bjorkman, Pamela J., Barnes, Christopher O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8095199/ https://www.ncbi.nlm.nih.gov/pubmed/33948592 http://dx.doi.org/10.1101/2021.04.23.441195

Ejemplares similares

Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies
por: Jette, Claudia A., et al.
Publicado: (2021)

Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies
por: Jette, Claudia A., et al.
Publicado: (2021)

Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes
por: Fan, Chengcheng, et al.
Publicado: (2022)

Mosaic RBD nanoparticles protect against multiple sarbecovirus challenges in animal models
por: Cohen, Alexander A., et al.
Publicado: (2022)

A naturally arising broad and potent CD4-binding site antibody with low somatic mutation
por: Barnes, Christopher O., et al.
Publicado: (2022)

Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models
por: Cohen, Alexander A., et al.
Publicado: (2022)

Antigen presentation dynamics shape the response to emergent variants like SARS-CoV-2 Omicron strain after multiple vaccinations with wild type strain
por: Yang, Leerang, et al.
Publicado: (2022)

Antigen presentation dynamics shape the antibody response to variants like SARS-CoV-2 Omicron after multiple vaccinations with the original strain
por: Yang, Leerang, et al.
Publicado: (2023)

SARS-CoV-2 spike glycosylation affects function and neutralization sensitivity
por: Zhang, Fengwen, et al.
Publicado: (2023)

Electron tomography visualization of HIV-1 fusion with target cells using fusion inhibitors to trap the pre-hairpin intermediate
por: Ladinsky, Mark S, et al.
Publicado: (2020)

Pan-sarbecovirus prophylaxis with human anti-ACE2 monoclonal antibodies
por: Zhang, Fengwen, et al.
Publicado: (2023)

Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies
por: Barnes, Christopher O., et al.
Publicado: (2020)

Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies
por: Barnes, Christopher O., et al.
Publicado: (2020)

Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice
por: Cohen, Alexander A., et al.
Publicado: (2021)

ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines
por: Hoffmann, Magnus A.G., et al.
Publicado: (2023)

Plasma Neutralization of the SARS-CoV-2 Omicron Variant
por: Schmidt, Fabian, et al.
Publicado: (2021)

Plasma neutralization properties of the SARS-CoV-2 Omicron variant
por: Schmidt, Fabian, et al.
Publicado: (2021)

Broad receptor tropism and immunogenicity of a clade 3 sarbecovirus
por: Lee, Jimin, et al.
Publicado: (2023)

Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape
por: Witte, Leander, et al.
Publicado: (2022)

B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV
por: Scheid, Johannes F., et al.
Publicado: (2021)

Multiviral Quartet Nanocages Elicit Broad Anti-Coronavirus Responses for Proactive Vaccinology
por: Hills, Rory A., et al.
Publicado: (2023)

Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody
por: Tortorici, M. Alejandra, et al.
Publicado: (2021)

HIV-1 CD4-binding site germline antibody–Env structures inform vaccine design
por: Dam, Kim-Marie A., et al.
Publicado: (2022)

Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization After Messenger RNA Vaccination and Variant Breakthrough Infection
por: Gaebler, Christian, et al.
Publicado: (2022)

Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies
por: Greaney, Allison J., et al.
Publicado: (2021)

Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies
por: Greaney, Allison J., et al.
Publicado: (2021)

Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines
por: Walls, Alexandra C., et al.
Publicado: (2021)

Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry
por: Park, Young-Jun, et al.
Publicado: (2022)

Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines
por: Walls, Alexandra C., et al.
Publicado: (2021)

Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice
por: Cohen, Alexander A., et al.
Publicado: (2021)

Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry
por: Park, Young-Jun, et al.
Publicado: (2021)

An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses
por: Liu, Lihong, et al.
Publicado: (2022)

A broadly neutralizing nanobody targeting the highly conserved S2 subunit of sarbecoviruses
por: Wang, Xiaoyun, et al.
Publicado: (2023)

Broad Sarbecovirus Neutralizing Antibodies Obtained by Computational Design and Synthetic Library Screening
por: Yang, Xuehua, et al.
Publicado: (2023)

A Recombinant Protein SARS-CoV-2 Candidate Vaccine Elicits High-titer Neutralizing Antibodies in Macaques.
por: Baisa, Gary, et al.
Publicado: (2021)

“A recombinant protein SARS-CoV-2 candidate vaccine elicits high-titer neutralizing antibodies in macaques.”
por: Baisa, Gary, et al.
Publicado: (2020)

Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies
por: Muecksch, Frauke, et al.
Publicado: (2021)

Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations
por: Muecksch, Frauke, et al.
Publicado: (2021)

Epistasis lowers the genetic barrier to SARS-CoV-2 neutralizing antibody escape
por: Witte, Leander, et al.
Publicado: (2023)

Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection in vivo
por: Schäfer, Alexandra, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_imctp9dtg3atdk60lh7qoth01s